In ESCC cells overexpressing SECTM1, the addition of TAK-779, a selective antagonist of CCR5, significantly reversed the migration and invasion induced by high SECTM1 expression (Figure 9E). This evidence concerns the gene CCR5 and esophageal squamous cell carcinoma.